537 related articles for article (PubMed ID: 9922152)
1. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
Lashuel HA; Lai Z; Kelly JW
Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152
[TBL] [Abstract][Full Text] [Related]
2. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions.
Lashuel HA; Wurth C; Woo L; Kelly JW
Biochemistry; 1999 Oct; 38(41):13560-73. PubMed ID: 10521263
[TBL] [Abstract][Full Text] [Related]
3. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
Lai Z; Colón W; Kelly JW
Biochemistry; 1996 May; 35(20):6470-82. PubMed ID: 8639594
[TBL] [Abstract][Full Text] [Related]
4. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
McCutchen SL; Lai Z; Miroy GJ; Kelly JW; Colón W
Biochemistry; 1995 Oct; 34(41):13527-36. PubMed ID: 7577941
[TBL] [Abstract][Full Text] [Related]
5. Effect of nitric oxide in amyloid fibril formation on transthyretin-related amyloidosis.
Saito S; Ando Y; Nakamura M; Ueda M; Kim J; Ishima Y; Akaike T; Otagiri M
Biochemistry; 2005 Aug; 44(33):11122-9. PubMed ID: 16101296
[TBL] [Abstract][Full Text] [Related]
6. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis.
Hurshman Babbes AR; Powers ET; Kelly JW
Biochemistry; 2008 Jul; 47(26):6969-84. PubMed ID: 18537267
[TBL] [Abstract][Full Text] [Related]
7. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid.
Kelly JW; Colon W; Lai Z; Lashuel HA; McCulloch J; McCutchen SL; Miroy GJ; Peterson SA
Adv Protein Chem; 1997; 50():161-81. PubMed ID: 9338081
[TBL] [Abstract][Full Text] [Related]
8. The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution.
Quintas A; Saraiva MJ; Brito RM
FEBS Lett; 1997 Dec; 418(3):297-300. PubMed ID: 9428731
[TBL] [Abstract][Full Text] [Related]
9. Transthyretin forms amyloid fibrils at physiological pH with ultrasonication.
Misumi Y; Ueda M; Fujimori H; Shinriki S; Meng W; Kim J; Saito S; Obayashi K; Uchino M; Ando Y
Amyloid; 2008 Dec; 15(4):234-9. PubMed ID: 19065294
[TBL] [Abstract][Full Text] [Related]
10. Why is Leu55-->Pro55 transthyretin variant the most amyloidogenic: insights from molecular dynamics simulations of transthyretin monomers.
Yang M; Lei M; Huo S
Protein Sci; 2003 Jun; 12(6):1222-31. PubMed ID: 12761393
[TBL] [Abstract][Full Text] [Related]
11. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured.
Jiang X; Smith CS; Petrassi HM; Hammarström P; White JT; Sacchettini JC; Kelly JW
Biochemistry; 2001 Sep; 40(38):11442-52. PubMed ID: 11560492
[TBL] [Abstract][Full Text] [Related]
12. Initial conformational changes of human transthyretin under partially denaturing conditions.
Yang M; Lei M; Bruschweiler R; Huo S
Biophys J; 2005 Jul; 89(1):433-43. PubMed ID: 15821170
[TBL] [Abstract][Full Text] [Related]
13. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro.
Colon W; Kelly JW
Biochemistry; 1992 Sep; 31(36):8654-60. PubMed ID: 1390650
[TBL] [Abstract][Full Text] [Related]
14. Hydration and packing are crucial to amyloidogenesis as revealed by pressure studies on transthyretin variants that either protect or worsen amyloid disease.
Ferrão-Gonzales AD; Palmieri L; Valory M; Silva JL; Lashuel H; Kelly JW; Foguel D
J Mol Biol; 2003 May; 328(4):963-74. PubMed ID: 12729768
[TBL] [Abstract][Full Text] [Related]
15. Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations.
Rodrigues JR; Simões CJ; Silva CG; Brito RM
Protein Sci; 2010 Feb; 19(2):202-19. PubMed ID: 19937650
[TBL] [Abstract][Full Text] [Related]
16. Clusterin regulates transthyretin amyloidosis.
Lee KW; Lee DH; Son H; Kim YS; Park JY; Roh GS; Kim HJ; Kang SS; Cho GJ; Choi WS
Biochem Biophys Res Commun; 2009 Oct; 388(2):256-60. PubMed ID: 19664600
[TBL] [Abstract][Full Text] [Related]
17. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation.
Sato T; Ando Y; Susuki S; Mikami F; Ikemizu S; Nakamura M; Suhr O; Anraku M; Kai T; Suico MA; Shuto T; Mizuguchi M; Yamagata Y; Kai H
FEBS Lett; 2006 Jan; 580(2):491-6. PubMed ID: 16386248
[TBL] [Abstract][Full Text] [Related]
18. Guanidine hydrochloride-induced denaturation and refolding of transthyretin exhibits a marked hysteresis: equilibria with high kinetic barriers.
Lai Z; McCulloch J; Lashuel HA; Kelly JW
Biochemistry; 1997 Aug; 36(33):10230-9. PubMed ID: 9254621
[TBL] [Abstract][Full Text] [Related]
19. Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin.
Shnyrov VL; Villar E; Zhadan GG; Sanchez-Ruiz JM; Quintas A; Saraiva MJ; Brito RM
Biophys Chem; 2000 Dec; 88(1-3):61-7. PubMed ID: 11152276
[TBL] [Abstract][Full Text] [Related]
20. Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding.
Trivella DB; Bleicher L; Palmieri Lde C; Wiggers HJ; Montanari CA; Kelly JW; Lima LM; Foguel D; Polikarpov I
J Struct Biol; 2010 Jun; 170(3):522-31. PubMed ID: 20211733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
